AstraZeneca’s Imfinzi gets FDA priority review for extensive-stage SCLC
Imfinzi holds approvals for the curative-intent setting of unresectable, stage III non-small cell lung cancer (NSCLC) following chemoradiation therapy across 54 countries, including the US, the European Union,